Thermostable variants of fibroblast growth factors
AssigneeHumanzyme Limited
InventorSoon Seog JEONG
Life of this patent
Estimating the term…
Abstract
The present technology relates to engineered human Fibroblast Growth Factor-2 (FGF2) proteins and methods of using the same. In particular, the methods and compositions relate to FGF2 mutants with increased thermostability compared to the wild-type protein and method for using the proteins in the culturing of embryonic stem cells.
Claims14
An isolated polynucleotide encoding a polypeptide selected from the group consisting of:
- (i) a variant of SEQ ID NO:2, or a fragment thereof, comprising at least one amino acid substitution selected from the group consisting of Q65L, Q65I, Q65V, N111A, N111G, C96S, and C96T.
- (ii) a polypeptide having at least 85% sequence identity to SEQ ID NO:2, or a fragment thereof, comprising at least one amino acid substitution selected from the group consisting of Q65L, Q65I, Q65V, N111A, N111G, C96S, and C96T.
An isolated polypeptide selected from the group consisting of:
- (i) a variant of SEQ ID NO:2, or a fragment thereof, comprising at least one amino acid substitution selected from the group consisting of Q65L, Q65I, Q65V, N111A, N111G, C96S, and C96T.
- (ii) a polypeptide having at least 85% sequence identity to SEQ ID NO:2, or a fragment thereof, comprising at least one amino acid substitution selected from the group consisting of Q65L, Q65I, Q65V, N111A, N111G, C96S, and C96T.
A method for maintaining human embryonic stem cells in an undifferentiated state comprising contacting human embryonic stem cells with an effective amount of a polypeptide comprising SEQ ID NO:8 or a variant of SEQ ID NO:4 comprising amino acid substitutions Q56I, N102G, and C87S.
Dependencies are inferred from the claim text.